Planmeca PULSE™ drives a new era of Planmeca’s CAD/CAM products

Planmeca introduced Planmeca PULSE™, a unified CAD/CAM platform designed to integrate intraoral/desktop scanners, milling units and 3D printers with an emphasis on precision, usability, speed, liberty and a single-vendor ecosystem. The privately held Helsinki-based group reported combined turnover of EUR 1.2 billion in 2024 and over 4,400 employees; the company will showcase PULSE across European congresses and a roadshow, a commercial push that could drive incremental equipment and software sales and improve clinic productivity but includes no forward financial guidance.

Analysis

Market structure: Planmeca’s PULSE pushes further vertical integration in CAD/CAM dentistry, benefiting integrated platform vendors, dental service chains and suppliers of milling/3D‑printing consumables. Expect incremental digital adoption to accelerate in advanced markets by ~3–5 percentage points annually over 2–3 years as same‑day workflows and financing programs lower clinic payback times. Independent scanner/software vendors and legacy dental labs that rely on manual workflows are the most exposed to share loss and pricing pressure.

Risk assessment: Near term (0–3 months) market moves are likely muted because Planmeca is private and adoption is capital‑cycle driven; short term (3–12 months) watch for order announcements from trade shows and distributor deals; long term (2–5 years) the shift materially raises capex but also concentrates aftermarket revenues. Tail risks: regulatory recalls/cyber breaches of an integrated ecosystem or an economic hit reducing elective dental spend by 10–20% would compress equipment orders. Hidden dependency: success hinges on distributor/service network and software interoperability with major EHR/orthodontic pipelines.

Trade implications: Favor public exposure to companies supplying scanners, printers and materials: consider XRAY (Dentsply Sirona) and DDD (3D Systems) as primary longs and ALGN (Align) as a tactical beneficiary of higher scan volumes. Use 3–6 month call spreads (20–30% OTM) on XRAY/ALGN to express upside from trade‑show/order catalysts while capping premium. Pair trade: long XRAY (2–3% portfolio) vs short HSIC (1–1.5%) to play platform capture vs distribution margin pressure.

Contrarian angle: The market may overrate immediate disruption—installed base replacement cycles are long (3–7 years) so revenue growth will be lumpy; public suppliers already priced for digital adoption, creating opportunities to buy dips after trade‑show verification. Unintended consequence: faster in‑chair workflows could reduce outsourced lab volumes, hurting specialized lab equipment makers and creating consolidation targets.

Key Decisions for Investors

• Establish a 2–3% long position in XRAY (Dentsply Sirona) within 2 weeks looking for 6–12 month upside from CAD/CAM capex growth; hedge with a 3–6 month 20–30% OTM call spread to limit premium outlay and sell if XRAY falls >15% from entry.
• Initiate a 1.5–2% long position in DDD (3D Systems) to capture printer/materials demand over 6–24 months; add on any pullback >10% and target +25–40% outperformance vs sector in 12–24 months.
• Put on a pair trade: long XRAY (size above) vs short HSIC (Henry Schein) 1:0.6 ratio (short 1–1.5% of portfolio) for 3–9 months to exploit platform adoption compressing distributor margin; unwind if HSIC outperforms XRAY by >10%.
• Buy 3–6 month call spreads on ALGN (20–30% OTM) sized to 0.5–1% of portfolio to play increased intraoral scan volumes; reassess after European roadshow and major trade shows (check for announced purchase orders within 30–90 days).